Orion Genomics, the Second Code Company, develops epigenetic research tools and molecular diagnostic products to fulfill the promise of personalized medicine. Orion's lead product is a simple blood-based test that is being developed to identify people at elevated risk for colorectal cancer. The company has active biomarker discovery programs to support our strategic alliances, and our internal product development pipeline, and in addition, the company offers genomics services to the medical, agricultural and bio-fuels research communities.
Orion Genomics develops oncology diagnostic products for cancer screening and therapy selection. We leverage our suite of proprietary technologies, MethylScope® and MethylScreen™, to find and interpret normal and abnormal epigenetic patterns of DNA methylation, also known as DNA's epigenetic code. We are currently identifying epigenetic biomarkers and employing them in the development of novel molecular diagnostic tests to find breast, lung, ovarian, colorectal and other diseases. Additionally, we are discovering biomarkers that can aid in the selection of best therapies for patients.